Singular Research Drops Coverage on BioSante Pharma After LibGel Results
In the report, Singular Research writes, "BioSante Pharmaceuticals (NASDAQ: BPAX) LibiGel® performed as expected, but a very strong placebo effectresulted in no statistically significant advantage for LibiGel®.We view this as a display of “mind over matter” fromnurturing women in the trial. Minimally, another clinical trial isnecessary for FDA approval; other new compounds in pipeline areseveral years from approval."
BioSante Pharmaceuticals closed today at $0.44, down 7.08% from market open.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.